Researchers uncover approach for possibly eradicating HIV infectionJune 22, 2009ST. LUCIE, FL - Researchers from the newly-established VGTI Florida and the University of Montreal have uncovered a possible method for eradicating HIV infection in the human body. The researchers have also revealed new information which demonstrates how HIV persists in the body - even in patients receiving drug treatments - and how the virus continues to replicate itself in individuals undergoing treatment. The research findings will be published in the online version of the journal Nature Medicine on June 21 and will be featured in an upcoming print edition of the journal. Medical advancements in the past 20 years have significantly increased the survival rates of AIDS patients. In fact, approximately 90 percent of patients infected with AIDS can survive with the disease as long as they are treated with a complex series of antiretroviral drugs. "Current medications allow us to control HIV and limit its progression in most cases," explained Rafick-Pierre Sékaly, Ph.D., current scientific director for VGTI Florida, a former scientist at the University of Montreal, and senior author of the research paper. "However, the medications do not eradicate the disease. Instead, the disease persists within the body - much like water in a reservoir - and is never fully destroyed. We believe our latest research may help scientists and physicians overcome this hurdle." The research team was able to identify a possible new way of attacking HIV by first identifying the specific cells where HIV infection persists in patients currently undergoing treatment. They found that the disease is able to survive within two subsets of memory T-cells. Memory T-cells are a portion of the body's immune system and have the ability to learn, detect and attack certain types of infectious diseases. By infecting cells within the body's own immune system, HIV is able to avoid antiviral treatments that are effective in stopping HIV in other cell types in the body. In-effect, HIV uses the body's own defense system as a hideout. The research team was also successful in identifying how these HIV-infected memory T-cells replenish themselves. When populating T-cells, HIV does not replicate itself as it does in other cell types on the body. Instead, HIV persists in memory T-cells through cell division - a finding that holds significant implications for possibly stopping the disease. "Based on this research, we believe one possible method for eliminating HIV in the body is to use a combined approach," said Dr. Sékaly. "We propose the use of medications that target viral replication of HIV throughout the body, in combination with drugs that prevent infected memory T-cells from dividing. We believe that by attacking the disease in these distinct two ways at once for an extended period of time, we can eliminate the reservoirs of HIV that currently persist within the human body, leaving an individual disease-free." The next step for researchers is to begin testing their proposed treatment method using animal models and newly developed therapies. "While this is a preliminary finding, we are hopeful that this research discovery will guide us in eradicating HIV infection in the body," said Dr. Sékaly. Oregon Health & Science University |
|||||||||||||||||||||
| Related HIV Infection Current Events and HIV Infection News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Many pregnant women avoid HIV screening in Africa 'Prevention is the best cure' is a common expression, but what happens if preventative measures are not used? A large proportion of pregnant Ugandan women are going out of their way not to be HIV tested, increasing the risk of mother-to-child transmission. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine. Global challenges and opportunities in fighting HIV/AIDS and neglected diseases Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. HIV care providers applaud Congress' extension of Ryan White program Medical providers on the front lines of HIV care applaud the U.S. Congress for extending the Ryan White HIV/AIDS Program, helping to ensure that more than half a million low-income, uninsured, or underinsured people living with HIV/AIDS have access to lifesaving care. Pitt researchers find candidates for new HIV drugs While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease. NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week. Continuing racial differences in HIV prevalence in US HIV prevalence among African Americans is ten times greater than the prevalence among whites. This racial disparity in HIV prevalence has persisted in the face of both governmental and private actions, involving many billions of dollars, to combat HIV. HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. More HIV Infection Current Events and HIV Infection News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||